


























	 On	 the	 account	 of	 the	 reported	 anticancer	 activity	 of	 2‐pyridone,	 a	 new	 series	 of	 ethyl‐1,6‐dihydropyridine‐3‐carboxylate	 (4a‐j),	 1‐oxo‐1,2‐dihydroisoquinoline‐7‐carbonitrile	 (6a‐h),













Compounds	 containing	 2‐pyridone	 moiety	 I‐IV	 as	 a	
precursor	 have	 proven	 to	 possess	 several	 biologically	
properties	 (Scheme	 1)	 [1‐6].	 In	 addition,	 different	 series	 of	
isoquinoline	containing	compounds	V	were	reported	to	possess	
substantial	 cytotoxicity	 [7].	 Furthermore,	 novel	 classes	 of	
chromenes	 bearing	 dithiazole	 VI	 or	 phenylthioamide	 VII	
moieties	 showed	 potent	 cytotoxicity	 [8],	 while	 chromene‐
carboxamides	VIII	 and	 carboxylates	proved	 potent	 anticancer	
activity	 on	 different	 cell	 lines	 and	 as	 inhibitors	 of	 tumor	
markers	 [9,10].	 Based	 on	 the	 above	 information	 and	 as	 a	
continuation	of	a	previous	work	on	anticancer	agents	[11‐16],	
we	 report	 the	 synthesis	 of	 novel	 2‐pyridone,	 isoquinoline,	







Chemicals	were	purchased	 from	Merck,	 Fluka	 and	Aldrich	
Chemical	 Companies.	 All	 yields	 refer	 to	 isolated	 products.	
Melting	 points	 are	 uncorrected	 and	 were	 determined	 on	 a	
Stuart	melting	point	 apparatus	 (Stuart	 Scientific,	 Redhill,	 UK).	
Elemental	 analysis	 (C,	 H	 and	 N)	 were	 performed	 on	 Perkin‐
Elmer	2400	analyser	(Perkin‐Elmer,	Norwalk,	CT,	USA)	at	The	
Microanalytical	 Laboratories	 of	 the	 Faculty	 of	 Science,	 Cairo	
University.	All	compounds	were	within	±0.4%	of	the	theoretical	
values.	 The	 IR	 spectra	 (KBr)	were	measured	 on	 Shimadzu	 IR	
110	 spectrophotometer	 (Shimadzu,	 Koyoto,	 Japan).	 1H	 NMR	
spectra	 were	 obtained	 on	 a	 Bruker	 proton	 NMR‐Avance	 300	
(300	 MHz)	 (Bruker,	 Munich,	 Germany),	 in	 DMSO‐d6	 as	 a	
solvent,	 using	 tetramethylsilane	 (TMS)	 as	 internal	 standard.	
Mass	 spectra	 were	 run	 on	 HP	 Model	 MS‐5988	 (Hewlett	
Packard,	 Palo,	 Alto,	 California,	 USA).	 All	 reactions	 were	
monitored	by	thin	layer	chromatograph	(TLC)	using	precoated	








cyanoacetate	 (1.13	 g,	 0.01	 mol)	 was	 refluxed	 for	 3	 h.	 The	
reaction	 mixture	 was	 concentrated	 and	 cooled.	 The	 obtained	
product	 was	 crystallized	 from	 ethanol	 to	 give	 compound	 3	
(Scheme	2).	Yield:	88%.	M.p.:	86‐88	C.	IR	(KBr,	ν,	cm–1):	3317	
(NH),	 3100	 (CH.	Arom.),	 2960,	 2870	 (CH	 aliph.),	 2260	 (C≡N),	
1670	 (C=O).	 1H	NMR	 (300	MHz,	DMSO‐d6,	,	 ppm):	1.2	 (t,	 3H,	
CH3,	J	=	0.66	Hz),	2.6	(q,	2H,	CH2,	J	=	0.66	Hz),	3.6	(s,	2H,	CH2),	
4.2	 (s,	1H,	NH,	 exchangeable	with	D2O),	7.0‐7.7	 (m,	4H,	Ar‐H).	










(0.113	 g,	 0.01	mol)	 in	 ethanol	 (50	mL)	 containing	 a	 catalytic	
amount	of	piperidine	was	refluxed	 for	4	h.	The	obtained	solid	


















NH2,	 exchangeable	with	 D2O).	 13C	 NMR	 (75	MHz,	 DMSO‐d6,	 ,	
ppm):	 13.4,	 15.2,	 25.1,	 31.9,	 62.9,	 86.1,	 114.3,	 115.0,	 117.3,	
119.8,	 122.1,	 125.8,	 127.4,	 130.6,	 131.0,	 133.2,	 136.7,	 140.9,	
162.7,	 163.2,	 164.8,	 168.7.	 MS	 (m/z,	 %):	 401	 (M+,	 5.1),	 90	


















4.3	 (q,	2H,	CH2,	 J	=	0.66	Hz),	7.2‐7.7	 (m,	9H,	Ar‐H),	8.3	 (s,	2H,	
NH2,	 exchangeable	with	D2O).	MS	 (m/z,	%):	 432	 (M+,	 5.7),	 74	
(100).	 Anal.	 calcd.	 for	 C23H20N4O5:	 C,	 63.88;	 H,	 4.66;	 N,	 12.96.	
Found:	C,	63.32;	H,	4.21;	N,	13.12%.	
Ethyl	 2‐amino‐5‐cyano‐1‐(3‐ethylphenyl)‐6‐oxo‐4‐(4‐nitro	
phenyl)‐1,6‐dihydro‐pyridine‐3‐carboxylate	 (4d):	 Yield:	 78%.	
M.p.:	140‐142	C.	IR	(KBr,	ν,	cm–1):	3227,	3209	(NH2),	3082	(CH	
arom.),	 2964,	 2872	 (CH	 aliph.),	 2194	 (C≡N),	 1680,	 1690	
(2C=O).	1H	NMR	(300	MHz,	DMSO‐d6,	,	ppm):	1.05	(t,	3H,	CH3,	J	
=	0.2	Hz),	1.3	(t,	3H,	CH3,	J	=	0.66	Hz),	2.6	(q,	2H,	CH2,	J	=	0.2	Hz),	
4.3	 (q,	2H,	CH2,	 J	=	0.66	Hz),	7.2‐7.7	 (m,	8H,	Ar‐H),	8.3	 (s,	2H,	
NH2,	 exchangeable	with	D2O).	MS	 (m/z,	%):	 432	 (M+,	 6.9),	 90	
(100).	 Anal.	 calcd.	 for	 C23H20N4O5:	 C,	 63.88;	 H,	 4.66;	 N,	 12.96.	
Found:	C,	63.50;	H,	4.90;	N,	13.12%.	
Ethyl	 2‐amino‐5‐cyano‐1‐(3‐ethylphenyl)‐6‐oxo‐4‐(4‐
pipronyl)‐1,6‐dihydro‐pyridine‐3‐carboxylate	 (4e):	 Yield:	 81%.	
M.p.:	160‐162	C.	IR	(KBr,	ν,	cm–1):	3238,	3209	(NH2),	3055	(CH	














7H,	 Ar‐H),	 8.3	 (s,	 2H,	NH2,	 exchangeable	with	D2O).	MS	 (m/z,	




Yield:	 87%.	 M.p.:	 189‐190	 C.	 IR	 (KBr,	 ν,	 cm–1):	 3223,	 3209	









phenyl)‐1,6‐dihydro‐pyridine‐3‐carboxylate	 (4h):	 Yield:	 90%.	
M.p.:	200‐201	C.	IR	(KBr,	ν,	cm–1):	3293,	3212	(NH2),	3085	(CH	




NH2,	 exchangeable	with	 D2O).	 13C	 NMR	 (75	MHz,	 DMSO‐d6,	 ,	
ppm):	 13.8,	 15.5,	 31.2,	 63.4,	 86.1,	 116.9,	 117.3,	 118.1,	 119.8,	













phenyl)‐1,6‐dihydro‐pyridine‐3‐carboxylate	 (4i):	 Yield:	 62%.	
M.p.:	 96‐98	C.	 IR	 (KBr,	 ν,	 cm–1):	3334,	3246	 (NH2),	3086	 (CH	





90	 (100).	 Anal.	 calcd.	 for	 C23H20BrN3O3:	 C,	 59.24;	 H,	 4.32;	 N,	
9.01.	Found:	C,	59.50;	H,	4.20;	N,	9.20%.	
Ethyl	 2‐amino‐5‐cyano‐1‐(3‐ethylphenyl)‐6‐oxo‐4‐(thiophen‐
2‐yl)‐1,6‐dihydro‐pyridine‐3‐carboxylate	 (4j):	 Yield:	 71%.	 M.p.:	
105‐107	 C.	 IR	 (KBr,	 ν,	 cm–1):	 3325,	 3209	 (NH2),	 3100	 (CH	












acetylacetone	 (1.00	 g,	 0.01	mol)	were	 refluxed	 in	 ethanol	 (50	
mL)	 containing	 piperidine	 (0.5	 mL)	 for	 5	 h.	 The	 reaction	
mixture	was	triturated	with	ethanol	and	the	solid	obtained	was	
recrystallized	 from	 dioxane	 to	 give	 compound	 5	 (Scheme	 2).	
Yield:	 86%.	 M.p.:	 198‐200	 C.	 IR	 (KBr,	 ν,	 cm–1):	 3100	 (CH	
arom.),	 2931,	 2872	 (CH	 aliph.),	 2210	 (C≡N),	 1660	 (C=O).	 1H	
NMR	(300	MHz,	DMSO‐d6,	,	ppm):	1.2	(t,	3H,	CH3,	J	=	0.66	Hz),	
1.5	(2s,	6H,	2CH3),	2.6	(q,	2H,	CH2,	J	=	0.66	Hz),	5.6	(s,	1H,	CH‐






General	 procedure:	 A	mixture	 of	 compound	5	 (1.5	 g,	 0.01	
mol),	benzylidine‐malononitrile	(0.01	mol)	 in	ethanol	(50	mL)	
containing	 (0.5	 mL)	 piperidine	 was	 refluxed	 for	 6	 h.	 The	
reaction	 mixture	 was	 cooled	 and	 poured	 onto	 ice	 water	









NMR	 (75	MHz,	 DMSO‐d6,	 ,	 ppm):	 12.9,	 21.3,	 26.4,	 33.8,	 96.0,	
100.3,	 116.8,	 118.2,	 118.9,	 119.8,	 121.7,	 124.5,	 126.8,	 127.6,	
130.9,	 133.4,	 134.8,	 139.0,	 140.9,	 142.4,	 144.6,	 147.8,	 151.3,	
158.4.	 Anal.	 calcd.	 for	 C26H23N3O:	 C,	 79.36;	 H,	 5.89;	 N,	 10.68.	
Found:	C,	79.50;	H,	5.70;	N,	10.40%.	
Amino‐2‐(3‐ethylphenyl)‐3‐methyl‐1‐oxo‐6‐(2‐methoxy	
phenyl)‐1,2‐dihydro‐	 isoquinoline‐7‐carbonitrile	 (6b):	 Yield:	
92%.	 M.p.:	 114‐116	 C.	 IR	 (KBr,	 ν,	 cm–1):	 3325,	 3209	 (NH2),	
3080	 (CH	 arom.),	 2931,	 2872	 (CH	 aliph.),	 2212	 (C≡N),	 1658	
(C=O).	1H	NMR	(300	MHz,	DMSO‐d6,	,	ppm):	1.2	(t,	3H,	CH3,	J	=	
0.66	Hz),	2.6	(q,	2H,	CH2,	J	=	0.66	Hz),	3.8	(s,	3H,	OCH3),	5.7	(s,	
1H,	 CH‐pyridine),	 6.9‐7.9	 (m,	 8H,	 Ar‐H),	 8.7	 (s,	 2H,	 NH2,	
exchangeable	 with	 D2O).	 MS	 (m/z,	 %):	 409	 (M+,	 5.12),	 105	













arom.),	 2931,	 2860	 (CH	 aliph.),	 2200	 (C≡N),	 1658	 (C=O).	 1H	
NMR	(300	MHz,	DMSO‐d6,	,	ppm):	1.2	(t,	3H,	CH3,	J	=	0.66	Hz),	











8H,	 Ar‐H),	 8.7	 (s,	 2H,	NH2,	 exchangeable	with	 D2O).	MS	 (m/z,	




85%.	 M.p.:	 106‐108	 C.	 IR	 (KBr,	 ν,	 cm–1):	 3340,	 3218	 (NH2),	








hoxyphenyl)‐1,2‐dihydro‐	 isoquinoline‐7‐carbonitrile	 (6f):	 Yield:	
79%.	 M.p.:	 117‐119	 C.	 IR	 (KBr,	 ν,	 cm–1):	 3364,	 3209	 (NH2),	
3080	 (CH	 arom.),	 2931,	 2836	 (CH	 aliph.),	 2213	 (C≡N),	 1658	
(C=O).	1H	NMR	(300	MHz,	DMSO‐d6,	,	ppm):	1.2	(t,	3H,	CH3,	J	=	
0.66	Hz),	2.6	(q,	2H,	CH2,	J	=	0.66	Hz),	3.7	(3S,	9H,	3OCH3),	5.7	(s,	





1,2‐dihydro‐	 isoquinoline‐7‐carbonitrile	 (6g):	 Yield:	 80%.	 M.p.:	
107‐110	 C.	 IR	 (KBr,	 ν,	 cm–1):	 3370,	 3230	 (NH2),	 3080	 (CH	
arom.),	 2920,	 2860	 (CH	 aliph.),	 2209	 (C≡N),	 1658	 (C=O).	 1H	
NMR	(300	MHz,	DMSO‐d6,	,	ppm):	1.2	(t,	3H,	CH3,	J	=	0.66	Hz),	
2.6	(q,	2H,	CH2,	J	=	0.66	Hz),	5.7	(s,	1H,	CH‐pyridine),	7.1‐7.7	(m,	
8H,	 Ar‐H),	 8.7	 (s,	 2H,	 NH2,	 exchangeable	with	 D2O).	MS	 (m/z,	
%):	 413	 (M+,	 35),	 105	 (100).	 Anal.	 calcd.	 for	 C25H20ClN3O:	 C,	
72.55;	H,	4.87;	N,	10.15.	Found:	C,	72.70;	H,	4.70;	N,	10.50%.	
8‐Amino‐2‐(3‐ethylphenyl)‐3‐methyl‐1‐oxo‐6‐(2,4‐dichloro	





7H,	 Ar‐H),	 8.7	 (s,	 2H,	 NH2,	 exchangeable	with	D2O).	MS	 (m/z,	






To	 a	 solution	 of	 compound	3	 (1.88	 g,	 0.01	mol)	 in	 acetic	
anhydride	(20	mL),	salicyladehyde	(1.22	g,	0.01	mol)	and	fused	
sodium	 acetate	 (0.8	 g,	 0.01	 mo)	 was	 added.	 The	 reaction	
mixture	was	refluxed	for	2	h,	cooled	and	the	solid	obtained	was	





(75	 MHz,	 DMSO‐d6,	 ,	 ppm):	 14.1,	 30.2,	 113.6,	 117.5,	 119.8,	








(1.22	 g,	 0.01	mol)	 and	 anhydrous	 ammonium	acetate	 (1.15	 g,	
0.15	mol)	 in	 ethanol	 (20	mL)	was	 refluxed	 for	 2	 h.	 The	 solid	
obtained	was	 recrystallized	 from	ethanol	 to	 give	 compound	8	
(Scheme	3).	Yield:	59%.	M.p.:	>300	C.	 IR	(KBr,	ν,	cm–1):	3344,	
3166	 (2NH),	 1720	 (C=O),	 1570	 (C=N).	 1H	 NMR	 (300	 MHz,	
DMSO‐d6,	,	ppm):	1.1	(t,	3H,	CH3,	J	=	0.2	Hz)	2.7	(q,	2H,	CH2,	J	=	
0.2	Hz),	6.9‐8.3	(m,	8H,	Ar‐H),	8.7	(s,	1H,	CH‐4),	9.5	(s,	1H,	NH	
imino,	 exchangeable	 with	 D2O),	 12.5	 (s,	 1H,	 NHCO,	
exchangeable	with	D2O).	13C	NMR	(75	MHz,	DMSO‐d6,	,	ppm):	
13.4,	31.2,	114.6,	115.8,	117.1,	119.8,	122.6,	123.3,	124.7,	126.2,	










Equimolar	 amounts	 of	 compounds	 7	 or	 8,	 malononitrile	
(0.66	g,	0.01mol)	anhydrous	ammonium	acetate	(1.115	g,	0.01	




chromeno(3,4‐c)pyridine‐1‐carbonitrile	 (9):	 Yield:	 61%.	 M.p.:	
>300	 C.	 IR	 (KBr,	 ν,	 cm–1):	 3090	 (CH	 arom.),	 2976,	 2865	 (CH	
aliph.),	 1684,	 1654	 (2C=O).	 1H	 NMR	 (300	 MHz,	 DMSO‐d6,	 ,	
ppm):	1.2	(t,	3H,	CH3,	J	=	0.66	Hz),	2.6	(q,	2H,	CH2,	J	=	0.66	Hz),	
6.9‐7.5	 (m,	 8H,	 Ar‐H).	 13C	 NMR	 (75	 MHz,	 DMSO‐d6,	 ,	 ppm):	
15.8,	34.3,	73.9,	116.5,	117.9,	118.0,	119.2,	122.6,	125.3,	126.1,	
127.0,	 127.8,	 128.9,	 129.3,	 135.6,	 141.2,	 153.6,	 156.4,	 158.8,	
161.4,	167.5.	MS	(m/z,	%):	357	(M+,	17.8),	76	(100).	Anal.	calcd.	
for	 C21H15N3O3:	 C,	 70.8;	 H,	 4.23;	 N,	 11.76.	 Found:	 C,	 75.40;	 H,	
4.60;	N,	4.10.	
2‐Amino‐3‐(3‐ethylphenyl)‐5‐imino‐4‐oxo‐4,5‐dihydro‐3H‐
chromeno[3,4‐c]pyridine‐1‐carbonitrile	 (10):	 Yield:	 58%.	 M.p.:	
>300	 C.	 IR	 (KBr,	 ν,	 cm–1):	 3312,	 3256,	 3216	 (NH,	 NH2),	
3070(CH	 arom.),	 2925,	 2853	 (CH	 aliph.),	 1690(C=O).	 1H	NMR	
(300	MHz,	DMSO‐d6,	,	ppm):	1.2[t,	3H,	CH3,	J	=	0.66	Hz),	2.6	(q,	
2H,	 CH2,	 J	 =	 0.66	 Hz),	 6.9‐7.8	 (m,	 8H,	 Ar‐H),	 8.7	 (s,	 1H,	 NH,	
exchangeable	 with	 D2O),	 10.1	 (s,	 2H,	 NH2,	 exchangeable	 with	








Ehrlich	 Ascites	 Carcinoma	 cells	 (EAC)	 were	maintained	 in	
female	 Swiss	 albino	 mice	 weighing	 25‐30	 g	 (the	 holding	
company	for	biological	products	and	vaccines,	VACSERA,	Cairo,	
Egypt)	 were	 housed	 at	 a	 constant	 temperature	 (24	 °C)	 with	
alternating	 12	 h	 light	 and	 dark	 cycles	 and	 fed	 standard	
laboratory	food	(Milad	CO.,	Cairo,	Egypt)	and	water	ad	libitum.	
All	 chemicals	 and	 reagents	 were	 of	 the	 highest	 grade	
commercially	 available.	 Facilities	 including	 animal	 house,	
biochemical	 equipments	 have	 been	 made	 available	 by	 the	
National	 Center	 for	 Radiation	 Research	 and	 Technology	
(NCRRT),	Atomic	Energy	Authority	(AEA),	Cairo,	Egypt.	Animal	
care	and	handling	was	done	according	to	the	guidelines	set	by	






Ehrlich	 Ascites	 Carcinoma	 cells	 (EAC)	 were	 obtained	 by	
needle	 aspiration	 of	 aseptic	 fluid	 from	 preinoculated	 mice;	
under	aseptic	conditions.	Tumor	cells	suspension	(2.5x106	per	
mL)	 was	 prepared	 in	 RPMI‐1640	 media.	 Tested	 compounds	
were	prepared	with	various	dilutions	by	dissolving:	100,	50,	25	
and	10	mg	of	the	tested	compounds	in	DMSO	(1	mL).	In	a	set	of	
sterile	 test	 tubes	 0.8	 mL	 RPMI‐1640	 media	 containing	
(glutamine,	 fetal	 calf	 serum	 as	 nutrient,	 streptomycin	 and	










Total	 cells	 =	 cells/mL	 x	 the	 original	 volume	 of	 fluid	 from	 which	 the	 cell	
sample	was	removed	 	 	 	 	 (2)	
	
%	cell	non‐viability	=	total	non‐viable	cells	(stained)	/	total	cells	x	100	
	 	 	 	 	 	 (3)	
	








100	 50	 25	 10	
4a 100 50 25 10	 25	 62.34
4b	 100	 50	 25	 10	 50	 119.9	
4c 100 60 40 10	 46	 106.48
4d	 60	 75	 50	 20	 25	 57.87	
4e	 100	 90	 70	 10	 45	 104.4	
4f	 100	 50	 25	 10	 50	 108.45	
4g 95 55 40 5	 48	 83.76
4h 90 70 30 10	 49	 116.38
4i 95 60 30 10	 49	 105.15
4j 95 65 20 5	 47	 119.59
6a 95 80 60 10	 23	 58.52
6b 50 10 0 0	 100	 244.5
6c	 100	 100	 60	 30	 15	 36.67	
6d	 100	 60	 40	 5	 46	 108.49	
6e	 100	 90	 50	 20	 25	 58.96	
6f	 100	 70	 40	 10	 43	 91.68	
6g 100 50 25 10	 50	 121.06
6h 100 60 30 5	 48	 107.14
7 30 0 0 0	 >100b	 ‐
8 20 0 0 0	 >100b	 ‐
9 100 80 25 10	 44	 123.24
10 100 90 60 30	 21	 58.98
Doxorubicin 100 68 30 24	 37	 68.13







The	 human	 tumor	 cell	 line	 (HEPG2)	 was	 available	 at	 the	
National	 Cancer	 Institute,	 Cairo,	 Egypt.	 Irradiation	 was	
performed	 in	 the	National	Cancer	 Institute,	Cairo,	Egypt	using	
Gamma	 cell‐40	 (60Co)	 source.	 The	 anticancer	 activity	 of	 the	




of	 cell	 to	 the	 wall	 of	 the	 plate.	 Tested	 compounds	 were	
dissolved	 in	DMSO	 and	diluted	with	 saline	 to	 the	 appropriate	
volume.	Different	concentrations	of	the	compounds	under	test	
(5.0,	12.5,	25.0	and	50.0	μM)	were	added	to	the	cell	monolayer.	




dissolved	 in	 1%	acetic	 acid.	 Unbounded	 dye	was	 removed	 by	




tumor	 cell	 line	 after	 the	 specified	 time.	 The	 concentration	














IC50	(µM)	5.0	 12.5 25.0 50.0
Surviving	fraction	(mean	±	SE)a	
Doxorubicin	 0.921	±	0.020	 0.846	±	0.020	 0.761	±	0.010	 0.494	±	0.030	 38.46	
4a	 0.845	±	0.002	 0.724	±	0.009 0.576	±	0.028 0.376	±	0.047	 31.2	
4d	 0.623	±	0.018	 0.523	±	0.031	 0.367	±	0.022	 0.271	±	0.012	 11.7	
6a	 0.723	±	0.012	 0.635	±	0.041	 0.523	±0.047	 0.244	±	0.022	 21.81	
6c	 0.922	±	0.064	 0.744	±	0.014 0.630	±	0.016	 0.436	±	0.012	 38.9	
6e	 0.876	±	0.064	 0.744	±	0.014 0.509	±	0.016	 0.312	±	0.012	 25.83







5.0	 12.5 25.0 50.0
4a	 0.587	±	0.01	 0.376	±	0.02	 0.329	±	0.05	 0.198	±	0.06	 5.03	
4d	 0.487	±	0.07	 0.398	±	0.01	 0.198	±	0.01	 0.100	±	0.08	 6.37	
6a	 0.355	±	0.01	 0.276	±	0.01 0.245	±	0.01 0.187	±	0.07	 2.68	
6c	 0.535	±	0.04	 0.498	±	0.01 0.287	±	0.01 0.198	±	0.06	 8.38	
6e	 0.589	±	0.04	 0.234	±	0.01 0.218	±	0.01 0.156	±	0.06	 6.04	






The	 most	 potent	 compounds	 resulted	 from	 the	 in	 vitro	
anticancer	 screening;	 compounds	 4a,	 4d,	 6a,	 6c,	 6e	 and	 10,	
were	selected	to	be	evaluated	again	for	their	in	vitro	anticancer	
activity	 alone	and	 in	combination	with	γ‐radiation.	This	study	
was	 conducted	 to	 evaluate	 the	 ability	 of	 these	 compounds	 to	
enhance	 the	 cell	 killing	 effect	 of	 γ‐radiation.	 Cells	 were	
subjected	to	a	single	dose	of	γ‐radiation	at	a	dose	level	of	8	Gy	
with	a	dose	rate	of	2	Gy/min.	 Irradition	was	performed	in	the	
National	 Cancer	 Institute,	 Cairo	University,	 using	Gamma	 cell‐







Schemes	 1	 and	 2	 outline	 the	 synthetic	 pathway	 used	 to	
obtain	 1,6‐dihydropyridines	 (4a‐j),	 1,2‐dihydroisoquinolines	
(6a‐h),	 2H‐chromenes	 (7	 and	 8)	 and	 3H‐chromeno[3,4‐
c]pyridines	 (9	 and	 10).	 The	 starting	 material,	 3‐cyano‐N‐(3‐
ethylphenyl)	 acetamide,	 3,	 was	 prepared	 via	 reaction	 of	 3‐
ethylaniline	 1	 with	 ethyl	 cyanoacetate	 2.	 Compound	 3	 was	
confirmed	by	elemental	analysis,	IR,	1H	NMR	and	mass	spectral	
data	(Scheme	1).	Upon	treatment	of	compound	3	with	required	
aldehyde	 and	 ethyl	 cyanoacetate	 in	 the	 presence	 of	 catalytic	
amount	of	piperidine	furnished	ethyl	4‐substituted‐2‐amino‐5‐
cyano‐1‐(3‐ethylphenyl)‐6‐oxo‐1,6‐dihydropyridine‐3‐
carboxylate,	 4a‐j.	 The	 structure	 of	 compounds	 4a‐j	 was	
deduced	from	elemental	analyses	and	spectral	data	(Scheme	1).	
Cycloaddition	 occurred	 upon	 treatment	 of	 compound	 3	 with	
acetylacetone	 to	 furnish	 2‐pyridone	 derivative	5	 which	 upon	
reaction	 with	 the	 corresponding	 arylidinemalononitriles	
yielded	 the	 correspondingisoquinoline	 derivatives	 6a‐h	
(Scheme	2).	
Furthermore,	Perkin	reaction	was	carried	when	compound	
3	 was	 reacted	 with	 salicyaldehyde	 in	 the	 presence	 ofacetic	
anhydride	containing	sodium	acetate	to	give	the	corresponding	
2‐oxochromene	 derivative	 7,	 while	 reaction	 of	 compound	 3	
with	 saliclyaldehyde	 in	 ammonium	 acetate	 furnished	 2‐
iminochromene	 8.	 The	 structure	 of	 compound	 7	 and	 8	 was	
supported	 in	 the	basis	 of	 elemental	 analyses,	 IR,	 1H	NMR	and	
mass	 spectral	 data.	 The	 chromene	 derivative	 7	 and	 8	 were	
further	 reacted	 with	 malononitrile	 in	 the	 presence	 of	
ammonium	 acetate	 to	 give	 the	 corresponding	 chromeno	
pyridine	 derivatives	 9	 and	 10,	 respectively	 (Scheme	 3).	 The	









the	 most	 effective	 antitumor	 agents	 used	 to	 produce	
regressions	 in	 acute	 leukemia’s,	 Hodgkin’s	 disease,	 and	 other	
lymphomas.	The	 relationship	between	survival	 ratio	and	drug	
concentration	 was	 plotted	 to	 obtain	 the	 survival	 curve	 of	
Ehrlich	Ascites	Carcinoma	(EAC)	cells	and	human	liver	cell	line	
(HEPG2).	 The	 response	 parameter	 calculated	 was	 IC50	 value	





The	 cytotoxicity	 of	 twenty‐two	 compounds	was	 examined	
on	 Ehrlich	 Ascites	 Carcinoma	 (EAC)	 cells.	 It	 is	 clear	 from	 the	
results	in	(Table	1)	that	in	the	series	of	1,6‐dihydropyridine	4a‐





nearly	as	potent	as	 the	 trimethoxy	derivative	4g	 (IC50	=	83.76	
µM).	On	the	other	hand,	the	4‐nitro	derivative	4d	(IC50	=	57.87	
µM)	 was	 found	 to	 be	 more	 potent	 than	 the	 corresponding										
3‐nitro	derivative	4c	(IC50	=	106.48	µM),	finally,	the	least	potent	
in	this	series	was	the	halogenated	derivatives	4h	and	4i	(IC50	=	
116.38	 and	 105.15	 µM).	 Concerning	 the	 series	 of	 1,2‐







µM)	 was	 found	 to	 be	 more	 potent	 than	 the	 corresponding										
3‐nitro	 derivative	 6d	 (IC50	 =	 108.49	 µM),	 while,	 the	 chloro	
derivatives	6g	and	6h	showed	nearly	equipotent	activity	(IC50	=	
121.06	 and	 107.14	 µM).	 Finally,	 the	 chromeno[3,4‐c]pyridone	
derivatives	 9	 and	 10	 (IC50	 =	 123.24	 and	 58.98	 µM)	 showed	








of	 the	 most	 potent	 six	 compounds	 resulted	 from	 EAC	 assay	
(compounds	4a,	4d,	6a,	6c,	6e	and	10).	We	can	conclude	from	
the	 results	 obtained	 from	 (Table	 2)	 that	 indeed	 these	
compounds	 showed	 potent	 activity	 on	 HEPG2	 cell	 line.	 The	
most	 potent	 was	 the	 4‐nitro	 dihydropyridone	 derivative	 4d	
(IC50	=	11.7	µM)	which	is	more	potent	than	doxorubicin	(IC50	=	









The	 rationale	 for	 combining	 chemotherapy	 and	
radiotherapy	 is	 based	mainly	 on	 two	 ideas,	 one	 being	 spatial	
cooperation,	which	 is	effective	 if	 chemotherapy	 is	sufficient	 to	
eradicate	subclinical	metastases	and	if	the	primary	local	tumor	
is	 effectively	 treated	 by	 radiotherapy.	 In	 this	 regard,	 no	
interaction	 between	 radiotherapy	 and	 chemotherapy	 is	
required.	 The	 other	 idea	 is	 the	 enhancement	 of	 radiation	
effects.	Cytotoxic	agents	can	enhance	radiation	effects	by	direct	
enhancement	 of	 the	 initial	 radiation	damage	by	 incorporating	
drugs	into	DNA,	inhibiting	cellular	repair,	accumulating	cells	in	
a	radiosensitive	phase	or	eliminating	radioresistant	phase	cells,	
eliminating	 hypoxic	 cells	 or	 inhibiting	 the	 accelerated	
repopulation	 of	 tumor	 cells	 [17].	 Consequently,	 the	 ability	 of	
the	most	 six	 active	 compounds	4a,	4d,	6a,	6c,	6e	 and	10,	 to	
enhance	the	cell	killing	effect	of	γ‐irradiation	was	studied.	From	
the	 results	obtained	 in	 (Table	2),	 compound	4a	 showed	an	 in	
vitro	 cytotoxic	 activity	 with	 IC50	 value	 of	 31.2	 μM,	 when	 the	
cells	 were	 subjected	 to	 different	 concentrations	 of	 the	
compound	 alone.	While,	when	 the	 cells	were	 subjected	 to	 the	
same	 concentrations	 of	 compound	 4a,	 and	 irradiated	 with	 a	
single	dose	of	 γ‐radiation	at	a	dose	 level	of	8	Gy,	 as	shown	 in	
(Table	3),	 the	 IC50	value	was	synergistically	decreased	 to	5.03	
μM.	 Similarly,	 compounds	4d,	6a,	6c,	6e	 and	10	 showed	 IC50	
values	 of	 11.7,	 21.81,	 38.9,	 25.83	 and	 32.2	 μM,	 respectively,	
when	 used	 alone,	 as	 shown	 in	 (Table	 2).	 The	 IC50	 value	 was	
decreased	 to	 6.37,	 2.68,	 8.38,	 6.04	 and	 3.35	 μM,	 respectively,	
when	 the	 cells	 were	 treated	 with	 compounds	 4d,	 6a,	6c,	6e,	
and	10	in	combination	with	γ‐radiation.	From	these	results,	we	
can	conclude	that	the	combination	of	compounds	4a,	4d,	6a,	6c,	
6e	 and	 10	 and	 ionizing	 radiation	 synergistically	 enhanced	





We	 report	 in	 this	 work	 the	 synthesis	 of	 new	 2‐pyridone,	
isoquinoline,	 chromene	 and	 chromenopyridone	 derivatives.	 It	
was	 clearly	 observed	 from	 the	 results	 of	 in‐vitro	 cytotoxic	
screening	 that	 some	 of	 the	 synthesized	 compounds	 exhibited	
significant	 anticancer	 activity	 on	 Ehrlich	 Ascites	 Carcinoma	
(EAC)	 and	 human	 liver	 tumor	 cell	 line	 (HEPG2).	 While,	
combining	 these	 compounds	 with	 radiation	 at	 the	 same	
concentrations	enhances	their	activity	which	demonstrates	the	
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